An evaluation of troublesome inter-menstrual bleeding in menorrhagic users of the LNG-IUS

Journal of Obstetrics and Gynaecology

Volumn 25, Issue 4, 2005, Pages 384-385

  Ibraheim, M ^a,b   Ikomi, A ^a  

^a BASILDON HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEVONORGESTREL;

AMENORRHEA; ARTICLE; BREAKTHROUGH BLEEDING; DEVICE REMOVAL; DRUG DELIVERY SYSTEM; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MENORRHAGIA; MENSTRUAL CYCLE; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; DRUG EFFECT; INTRAUTERINE CONTRACEPTIVE DEVICE; UTERUS; UTERUS BLEEDING;

FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MENORRHAGIA; RETROSPECTIVE STUDIES; UTERINE HEMORRHAGE; UTERUS;

EID: 24644461133     PISSN: 01443615     EISSN: None     Source Type: Journal    
DOI: 10.1080/01443610500134340     Document Type: Article

References (4)

1. Crosignani PG, Vercellini P, Mosconi P, Oldani S, Cortesi I, De Giorgi O. 1997. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in treatment of dysfunctional uterine bleeding. Obstetrics and Gynecology 90:257-263.
2. Jones RL, Critchley HO. 2000. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Human Reproduction 15(suppl 3):162-172.
3. Jensen JT. 2002. Noncontraceptive applications of the levonorgestrel intrauterine system. Current Women's Health Reports 2:417-422.
4. Rutanen EM, Salmi A, Nyman T. 1997. mRNA expression of insulin like growth factor-I (IGF-I) is suppressed and those of IGF-II and IGF-binding protein-1 are constantly expressed in the endometrium during use of an intrauterine levonorgestrel system. Molecular Human Reproduction 3:749-754.